Volume 27, Number 2—February 2021
CME ACTIVITY - Synopsis
Plasmodium ovale wallikeri and P. ovale curtisi Infections and Diagnostic Approaches to Imported Malaria, France, 2013–2018
Table 3
Biologic and clinical characteristics of Plasmodium ovale wallikeri and P. ovale curtisi infections, France, January 2013–December 2018*
Characteristic | P. ovale curtisi, n = 309 | P. ovale wallikeri, n = 368 | p value |
---|---|---|---|
Parasite density, parasites/µL, median (IQR) | 4,500 (1,094–10,197) | 3,970 (598–9,240) | 0.112 |
Leucocyte count, G/L, median (IQR) | 5.6 (4.4–7.1) | 5.2 (4.1–6.5) | 0.0501 |
Hemoglobin, g/L, median (IQR) |
127 (113–140) |
126 (114–139) |
0.855 |
Platelet count, G/L, median (IQR) | 111 (84–145) | 94 (70–130) | <0.001 |
<75 | 56 (19.4) | 104 (31) | |
75–150 | 168 (58.1) | 174 (51.9) | 0.003 |
>150 |
65 (22.5) |
57 (17.1) |
|
Severe thrombocytopenia | 13 (4.5) | 25 (7.5) | 0.123 |
Diagnostic delay, d, median (IQR) |
5 (3–7) |
4 (2–7) |
0.583 |
Delay between return from endemic country and onset of symptoms, d, median (IQR) | 72 (18–208) | 34 (10–95) | <0.001 |
<50 days |
87 (42.4) |
150 (59.5) |
<0.001 |
Symptoms | |||
Fever | 262 (95.6) | 316 (97.8) | 0.125 |
Arthralgia or myalgia | 120 (54.8) | 138 (57.7) | 0.525 |
Asthenia | 108 (58) | 133 (61.3) | 0.506 |
Headache | 151 (68.6) | 201 (75.3) | 0.103 |
Anorexia | 5 | 4 | |
Diarrhea | 13 | 18 | |
Abdominal pain | 28 | 29 | |
Nausea | 16 | 20 | |
Vomiting | 24 | 13 | |
Cough |
6 |
12 |
|
Clinical categorization | 0.927 | ||
Uncomplicated malaria | 293 (97.7) | 335 (97.4) | |
Severe malaria | 3 (1) | 5 (1.5) | |
Asymptomatic |
4 (1.3) |
4 (1.1) |
|
Admission to hospital | 158 (55.4) | 196 (60.3) | 0.243 |
Duration of hospitalization, d, median (IQR) | 2 (1–3) | 3 (1–4) | 0.0732 |
Intensive- or intermediate-care hospitalization | 1 (2.2) | 7 (11.3) | 0.134 |
Conventional hospitalization |
46 (97.8) |
55 (88.7) |
|
Treatment | 0.00359 | ||
Chloroquine | 147 (54.8) | 152 (47.8) | |
Artemisinin therapy | 46 (17.1) | 93 (29.2) | |
Artemeter/lumefantrine | 11 (25.5) | 39 (41.9) | |
Artesunate | 2 (4.3) | 5 (5.4) | |
Arteminol/piperaquine | 33 (70.2) | 49 (52.7) | |
Atovaquone/proguanil | 64 (23.9) | 64 (20.1) | |
Mefloquine | 3 (1.2) | 0 (0) | |
Quinine | 8 (3) | 9 (2.9) |
*Values are no. (%) patients except as indicated. IQR, interquartile range.
1Additional members of the French National Reference Center for Imported Malaria Study Group who contributed data are listed at the end of this article.